Spero Therapeutics
SPRO

Spero Therapeutics (SPRO) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$5.00Jan 30, 2025
Evercore ISI GroupDowngradedOutperform → In-Line$5.00Dec 20, 2024
HC Wainwright & Co.MaintainedBuy$5.00Dec 2, 2024
TD CowenDowngradedBuy → HoldNov 18, 2024
Cantor FitzgeraldMaintainedOverweightNov 15, 2024
HC Wainwright & Co.MaintainedBuy$5.00 from $7.00Nov 4, 2024
HC Wainwright & Co.MaintainedBuy$7.00Oct 3, 2024
HC Wainwright & Co.MaintainedBuy$7.00Aug 6, 2024
Cantor FitzgeraldMaintainedOverweightAug 6, 2024
TD CowenUpgradedHold → BuyAug 6, 2024
HC Wainwright & Co.MaintainedBuy$7.00May 16, 2024
Cantor FitzgeraldMaintainedOverweightApr 4, 2024
HC Wainwright & Co.MaintainedBuy$7.00Mar 18, 2024
HC Wainwright & Co.MaintainedBuy$7.00Nov 14, 2023
HC Wainwright & Co.MaintainedBuy$7.00Sep 5, 2023
HC Wainwright & Co.MaintainedBuy$7.00 from $6.00Aug 14, 2023
HC Wainwright & Co.MaintainedBuy$6.00Aug 1, 2023
HC Wainwright & Co.MaintainedBuy$6.00Jul 20, 2023

Frequently asked questions

  • What is the latest analyst rating on SPRO?

    On Jan 30, 2025, HC Wainwright & Co. maintained Spero Therapeutics at Buy with a price target of $5.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.